Jun 22, 2020
Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual Meeting
Jun 18, 2020
Lyell Immunopharma and PACT Pharma Announce Research and Clinical Development Partnership
May 15, 2020
GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming American Association for Cancer Research (AACR) Meeting II
May 14, 2020
Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020
Apr 28, 2020
Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR(TM) GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting
Mar 26, 2020
Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update
Feb 05, 2020
Obsidian Therapeutics Announces Formation of Scientific Advisory Board
Feb 03, 2020
Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications
Nov 06, 2019
Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019
Oct 30, 2019
AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR-T cells for Patients with Advanced, Refractory Thyroid Cancer
Aug 30, 2019
CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma
Aug 15, 2019
Phio Pharmaceuticals and Helmholtz Zentrum München to Collaborate on Novel Targets for the Use of Self-Delivering RNAi In T Cell and NK Cell Adoptive Cell Therapy Therapeutics
Jul 23, 2019
Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B
Apr 08, 2019
Researchers Report SX-682 Could Enhance Multiple Forms of T Cell-Based Immunotherapies in Solid Tumors
Mar 28, 2019
TCR2 Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual Meeting
Mar 05, 2019
NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer
Feb 21, 2019
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
Jan 17, 2019
Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Journey From Target to T Cell Product: A Platform to Identify Opportunities and Overcome Challenges, 2018 by DelveInsight
Dec 04, 2018
Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13
Dec 03, 2018
Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Clinical Development of DEACT Platform